Terry J. Fry, M.D. Faculty and Director of Cancer Immunotherapy, University of Colorado
Before joining the Anschutz Medical Campus community, Dr. Fry was a Tenure-Track Investigator at the Pediatric Oncology Branch of the National Cancer Institute. Prior to that, he served as Chief of Blood and Marrow Transplantation at Children’s National Medical Center, a position he held until 2010 when he returned to the Pediatric Oncology Branch as Head of the Hematologic Malignancies Section. Dr. Fry received his M.D. from Georgetown University in 1992. After completing a pediatric residency at Georgetown in 1995, he served as Chief Pediatric Resident. Dr. Fry undertook fellowship training in pediatric hematology/oncology at Johns Hopkins University and established a research program focused on the immunology of stem cell transplantation as a platform for cancer immunotherapy. Dr. Fry was among the first scientists to investigate the potential to insert modified genes into a child’s own T-cells to target CD19, a surface protein found on nearly all cells affected by acute lymphoblastic leukemia (ALL). The first product using this technology, called chimeric antigen T-cell (CAR-T cells), was approved by the FDA for pediatric use in August 2017 and achieved an astonishing 80 percent remission rate in children with highly refractory leukemia resistant to all other therapies including conventional bone marrow transplant. Dr. Fry is a member of multiple societies including the American Society of Hematology, the American Association of Immunology, the Children’s Oncology Group where he serves as Vice Chair of Cell Therapy, the American Society of Blood and Marrow Transplantation, and he was elected into the American Society of Clinical Investigation this past year. He also serves in leadership positions in the Oncology Strategy Group in the Pediatric Blood and Marrow Transplant Consortium and the Cellular Therapy Consortium.